EQT Life Sciences

• Nouscom

  Series D

• Vico Therapeutics

  Series B, Lead, Jan 5, 2024

Sources: globenewswire.com, prnewswire.com

• Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

  Employment, Mar 19, 2026

• Performance of a [18F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies

  Employment, Sep 25, 2023

• Plasma Oligomer β-Amyloid and White Matter Microstructural Integrity in Cognitively Normal Older Adults According to Cerebral Amyloid Deposition

  Employment, Jan 1, 2023

• Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer's disease

  Employment, Aug 5, 2022

Sources: pubmed.ncbi.nlm.nih.gov